This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Medtronic Inc. (MDT): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Medtronic ( MDT) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.8%. By the end of trading, Medtronic fell $0.82 (-1.6%) to $51.53 on heavy volume. Throughout the day, 11,117,931 shares of Medtronic exchanged hands as compared to its average daily volume of 4,044,600 shares. The stock ranged in price between $51.11-$52.60 after having opened the day at $51.98 as compared to the previous trading day's close of $52.35. Other companies within the Health Care sector that declined today were: Escalon Medical Corporation ( ESMC), down 15.3%, Lakeland Industries ( LAKE), down 14.3%, AMAG Pharmaceuticals ( AMAG), down 10.7% and Neptune Technologies & Bioressources ( NEPT), down 9.6%.

  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $50.6 billion and is part of the health services industry. The company has a P/E ratio of 15.2, below the S&P 500 P/E ratio of 17.7. Shares are up 27.6% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Medtronic a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, MannKind Corporation ( MNKD), down 16.2%, AcelRx Pharmaceuticals ( ACRX), down 13.4%, TranS1 ( TSON), down 13.2% and iBio ( IBIO), down 10.8% , were all gainers within the health care sector with Cubist Pharmaceuticals ( CBST) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 17,347.46 +152.04 0.88%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,620.6490 +54.5110 1.19%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs